2025年12月18日，宜明昂科生物医药技术（上海）股份有限公司（简称“宜明昂科”，香港交易所股票代码：01541.HK）宣布，公司自主研发的、同时靶向CD47和CD20的双特异性抗体-受体重组蛋白药物阿沐瑞芙普α（皮下注射制剂）IMM0306S用于治疗系统性红斑狼疮（SLE）的临床试验申请（IND）已正式获得国家药品监督管理局（NMPA）受理（受理号：CXSL2501092）。这标志着公司在...
Source Link2025年12月18日，宜明昂科生物医药技术（上海）股份有限公司（简称“宜明昂科”，香港交易所股票代码：01541.HK）宣布，公司自主研发的、同时靶向CD47和CD20的双特异性抗体-受体重组蛋白药物阿沐瑞芙普α（皮下注射制剂）IMM0306S用于治疗系统性红斑狼疮（SLE）的临床试验申请（IND）已正式获得国家药品监督管理局（NMPA）受理（受理号：CXSL2501092）。这标志着公司在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.